72 related articles for article (PubMed ID: 21791570)
1. Lapatinib, a preventive/therapeutic agent against mammary cancer, suppresses RTK-mediated signaling through multiple signaling pathways.
Li J; Cho YY; Langfald A; Carper A; Lubet RA; Grubbs CJ; Ericson ME; Bode AM
Cancer Prev Res (Phila); 2011 Aug; 4(8):1190-7. PubMed ID: 21791570
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
4. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
6. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
Christov K; Grubbs CJ; Shilkaitis A; Juliana MM; Lubet RA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5488-96. PubMed ID: 17875779
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
Decensi A; Puntoni M; Pruneri G; Guerrieri-Gonzaga A; Lazzeroni M; Serrano D; Macis D; Johansson H; Pala O; Luini A; Veronesi P; Galimberti V; Dotti MC; Viale G; Bonanni B
Cancer Prev Res (Phila); 2011 Aug; 4(8):1181-9. PubMed ID: 21685235
[TBL] [Abstract][Full Text] [Related]
8. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Ma C; Niu X; Luo J; Shao Z; Shen K
Cancer Sci; 2010 Oct; 101(10):2220-6. PubMed ID: 20701607
[TBL] [Abstract][Full Text] [Related]
10. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
11. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
Ahmad N; Gali H; Javed S; Agarwal R
Biochem Biophys Res Commun; 1998 Jun; 247(2):294-301. PubMed ID: 9642119
[TBL] [Abstract][Full Text] [Related]
12. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
Coley HM; Shotton CF; Ajose-Adeogun A; Modjtahedi H; Thomas H
Biochem Pharmacol; 2006 Oct; 72(8):941-8. PubMed ID: 16934227
[TBL] [Abstract][Full Text] [Related]
13. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
Spector NL; Xia W; Burris H; Hurwitz H; Dees EC; Dowlati A; O'Neil B; Overmoyer B; Marcom PK; Blackwell KL; Smith DA; Koch KM; Stead A; Mangum S; Ellis MJ; Liu L; Man AK; Bremer TM; Harris J; Bacus S
J Clin Oncol; 2005 Apr; 23(11):2502-12. PubMed ID: 15684311
[TBL] [Abstract][Full Text] [Related]
14. Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Lubet RA; Steele VE; Juliana MM; Bode A; Moeinpour F; Grubbs CJ
Oncol Rep; 2018 Sep; 40(3):1545-1553. PubMed ID: 29565450
[TBL] [Abstract][Full Text] [Related]
15. The dual targeting of EGFR and ErbB2 with the inhibitor Lapatinib corrects high glucose-induced apoptosis and vascular dysfunction by opposing multiple diabetes-induced signaling changes.
Benter IF; Sarkhou F; Al-Khaldi AT; Chandrasekhar B; Attur S; Dhaunsi GS; Yousif MH; Akhtar S
J Drug Target; 2015; 23(6):506-18. PubMed ID: 26114862
[TBL] [Abstract][Full Text] [Related]
16. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
Srivastava S; Mohibi S; Mirza S; Band H; Band V
Cell Cycle; 2017 Aug; 16(16):1515-1525. PubMed ID: 28759294
[TBL] [Abstract][Full Text] [Related]
18. Effect of intermittent dosing regimens of erlotinib on methylnitrosourea-induced mammary carcinogenesis.
Lubet RA; Szabo E; Iwata KK; Gill SC; Tucker C; Bode A; Steele VE; Juliana MM; Nicastro HL; Grubbs CJ
Cancer Prev Res (Phila); 2013 May; 6(5):448-54. PubMed ID: 23531447
[TBL] [Abstract][Full Text] [Related]
19. Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
Lubet RA; Szabo E; Christov K; Bode AM; Ericson ME; Steele VE; Juliana MM; Grubbs CJ
Mol Cancer Ther; 2008 Apr; 7(4):972-9. PubMed ID: 18375820
[TBL] [Abstract][Full Text] [Related]
20. Novel Effects of Lapatinib Revealed in the African Trypanosome by Using Hypothesis-Generating Proteomics and Chemical Biology Strategies.
Guyett PJ; Behera R; Ogata Y; Pollastri M; Mensa-Wilmot K
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
